An independent two-stage DCF analysis by a frontier AI model.
" data-astro-cid-mrpccrzy> Stryker's revenue grew over 11% in FY2025, supported by strong demand in MedSurg and Neurotechnology. FCF growth was highly volatile historically but has robust momentum now. 11% reflects expected continued growth driven by Mako robot placements, an aging population, and M&A integration.
" data-astro-cid-mrpccrzy> Stryker's revenue grew over 11% in FY2025, supported by strong demand in MedSurg and Neurotechnology. FCF growth was highly volatile historically but has robust momentum now. 11% reflects expected continued growth driven by Mako robot placements, an aging population, and M&A integration.
" data-astro-cid-mrpccrzy> Stryker's revenue grew over 11% in FY2025, supported by strong demand in MedSurg and Neurotechnology. FCF growth was highly volatile historically but has robust momentum now. 11% reflects expected continued growth driven by Mako robot placements, an aging population, and M&A integration.
Intrinsic value per share under varying discount rate and terminal growth rate assumptions.
| WACC ↓ / Terminal → | 7.0% | 7.5% | 8.0% | 8.5% | 9.0% |
|---|---|---|---|---|---|
| 7.0% | $25.10 | $25.10 | $25.10 | $25.10 | $25.10 |
| 7.5% | $25.10 | $25.10 | $25.10 | $25.10 | $25.10 |
| 8.0% | $25.10 | $25.10 | $25.10 | $25.10 | $25.10 |
| 8.5% | $25.10 | $25.10 | $25.10 | $25.10 | $25.10 |
| 9.0% | $25.10 | $25.10 | $25.10 | $25.10 | $25.10 |
■ Undervalued vs current price ■ Overvalued vs current price
Gemini 3.1. "Stryker Corporation (SYK) Intrinsic Value: A DCF Analysis." westmountfundamentals.com, March 18, 2026.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.